Entasis Therapeutics Announces Multiple Presentations at ID Week 2019
October 3, 2019
CEO Dr. Manos Perros participated in Industry Panel today

WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced its participation in an industry panel presentation and delivery of two poster presentations demonstrating the antibacterial activity of lead candidate sulbactam-durlobactam at ID Week 2019, taking place October 2-6 at the Walter E. Washington Convention Center in Washington, D.C.

During the well-attended panel presentation, Dr. Perros discussed the industry’s response to addressing antimicrobial resistance and provided his perspective on ways to reinvigorate antibiotic development. The panel was facilitated by Drs. Helen Boucher and Vance Fowler and additional panelists included representatives from Needham & Co., CARB-X, Vivo Ventures and OrbiMed.

The poster presentations support the continued development of sulbactam-durlobactam against drug resistant Acinetobacter in the ongoing ATTACK Phase 3 clinical trial and demonstrate potential of the combination as an effective new therapy for the treatment of the challenging pathogen Burkholderia, respectively.

“ID Week represents an important opportunity for academia and industry to converge to discuss the latest advancements in tackling infectious diseases. I’m particularly honored this year to have participated in the moderated panel session to discuss ways to improve the environment for antibiotic development, especially in light of the challenges the field has undergone this year alone,” said Manos Perros, Chief Executive Officer, Entasis Therapeutics.

Details of the Presentations are as follows:

Panel Presentation: We’re Part of the Problem: How ID Killed Antibiotic Development

- **Presenter:** Manos Perros, PhD; CEO of Entasis Therapeutics
- **Timing:** Thursday, October 3rd at 10:30 – 11:45 a.m. ET
- **Location:** 151 AB

Poster #694: *In vitro* Antibacterial Activity of Sulbactam-Durlobactam (ETX2514SUL) against 121 Recent *Acinetobacter baumannii* Isolated from Patients in India

- **Session:** Novel Antimicrobials and Approaches Against Resistant Bugs
- **Presenter:** Alita Miller, PhD; Head of Biology at Entasis Therapeutics
- **Timing:** Thursday, October 3rd at 12:15 – 1:30 p.m. ET
- **Location:** Exhibit Hall BC
- **Results summary:** Overall, these data support the continued development of sulbactam-durlobactam for the treatment of antibiotic-resistant infections caused by *A. baumannii*. Specifically, the study showed durlobactam effectively restored sulbactam antibacterial activity against a collection of recent *Acinetobacter baumannii* clinical isolates from six cities across India. The combination of sulbactam-durlobactam was significantly more potent against multi-drug resistant isolates than all the comparator antibiotics, except colistin. The study also indicated that rates of carbapenem resistance in *A. baumannii* may be even higher in India than previously estimated.

Poster #709: *In vitro* Antibacterial Activity and *in vivo* Efficacy of Sulbactam-Durlobactam (ETX2514SUL) against Pathogenic *Burkholderia* Species

- **Session:** Novel Antimicrobials and Approaches Against Resistant Bugs
Results summary: Overall, these preliminary preclinical data demonstrate robust in vitro and in vivo antibacterial activity of sulbactam-durlobactam against *Burkholderia* species and suggest this combination may be an effective new therapy for the treatment of these challenging pathogens. Specifically, durlobactam restored sulbactam antibacterial activity against a collection of *B. mallei* and *B. pseudomallei* isolates. The combination was efficacious in a murine model of melioidosis. Furthermore, sulbactam-durlobactam was more efficacious over time in this model than either comparator agent, with 90% vs. 60% survival at day 35 and 60% vs. <40% survival observed at day 45 for sulbactam-durlobactam or comparators, respectively.